NeuroScientific Biopharmaceuticals Ltd.
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. Our vision is to transform how the pharmaceutical industry approaches the understanding and treatment of neurodegenerative disease such as Alzheimer’s Disease. We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
Biopharmaceutical innovation and world class R&D
NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.
The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).
EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II.
Unique Mechanism of Action
The mechanism of action of EmtinB occurs via binding to surface-based cell receptors belonging to the LDLR family, which activate intracellular signaling pathways that “turn on” survival processes of neurons and modulate neuroinflammation.
EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.